GENEONE LIFE SCIENCE, INC.
The company has established pilot mRNA manufacturing capabilities in a purpose built GMP production suite at its current facility in
mRNA therapeutics are rapidly advancing in the clinic with a range of potential applications from gene therapies and gene editing to RNA-based vaccines. According to VGXI's CEO Young Park, 'We are building on nearly 20 years of plasmid DNA manufacturing experience, making VGXI ideally poised to provide industry-leading solutions for high purity RNA production and testing.' Contact VGXI today to learn more.
ABOUT VGXI, INC.
ABOUT
ABOUT
Houston Methodist comprises a leading academic medical center and seven community hospitals serving the
The RNAcore at the
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as 'anticipate,' 'estimate,' 'expect,' 'project,' 'intend,' 'plan,' 'believe,' and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.
Contact:
Tel: 281-296-7300
(C) 2019 Electronic News Publishing, source
